Thrombolytics: Clot-Busting Drugs for Stroke, MI, and PE

Thrombolytics — also called clot busters — are high-risk, time-critical drugs used to dissolve clots in acute ischemic stroke, myocardial infarction, and massive pulmonary embolism. This note reviews the key agents, time windows, contraindications, and nursing safety priorities most often tested on nursing exams.

Thrombolytic Drugs

• Alteplase (tPA) — used for ischemic stroke, MI, and PE
• Tenecteplase (TNK-tPA) — used for MI
• Reteplase (rPA) — used for MI

Indications

• Acute ischemic stroke
• Acute myocardial infarction (STEMI)
• Massive pulmonary embolism

Time Windows

Time is critical — administering outside the window dramatically increases risk and reduces benefit.

• Ischemic stroke: within 3–4.5 hours of symptom onset
• STEMI: within 12 hours of symptom onset
• Massive PE: as soon as possible if the patient is unstable

Mechanism of Action

• Convert plasminogen to plasmin
• Plasmin breaks down fibrin clots
• Blood flow is restored to ischemic tissue

Absolute Contraindications

• Active internal bleeding
• History of hemorrhagic stroke
• Recent surgery or trauma
• Uncontrolled hypertension
• Recent head injury

Life-Threatening Risks

• Intracranial hemorrhage — fatal bleeding risk
• GI bleeding — severe blood loss
• Reperfusion dysrhythmias — cardiac instability after blood flow is restored

Nursing Safety Rules

• Confirm the exact time of symptom onset before giving
• Control blood pressure before administration
• Obtain baseline coagulation labs
• Avoid IM injections and invasive procedures during therapy
• Monitor neurological status closely

Common Exam Traps

• Administering outside the time window
• Missing a history of hemorrhagic stroke
• Giving the drug with uncontrolled hypertension
• Confusing thrombolytics (clot busters) with anticoagulants (clot preventers)
• Ignoring a sudden headache or neuro decline (possible intracranial bleed)

Key takeaways

• Thrombolytics dissolve existing clots by converting plasminogen to plasmin.
• Alteplase (tPA) is the most commonly tested agent.
• Strict time windows apply: 3–4.5 hours for ischemic stroke, 12 hours for STEMI.
• Bleeding — especially intracranial hemorrhage — is the biggest risk.
• Hemorrhagic stroke is an absolute contraindication.
• A sudden neuro change during therapy is an emergency until proven otherwise.